Export 55 results:
Author Title Type [ Year(Asc)]
Filters: First Letter Of Title is F  [Clear All Filters]
2022
S. M. Raja, Guptill, J. T., Juel, V. C., Walter, E. B., Cohen-Wolkowiez, M., Hill, H., Sendra, E., Hauser, B., Jackson, P., Tomic, M., Espinoza, Y., and Swamy, G. K., “First-in-Human Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single Doses of NTM-1633, a Novel Mixture of Monoclonal Antibodies against Botulinum Toxin E.”, Antimicrob Agents Chemother, vol. 66, no. 4, p. e0173221, 2022.
2021
L. Pauleikhoff, Heeren, T. F. C., Gliem, M., Lim, E., Pauleikhoff, D., Holz, F. G., Clemons, T., Balaskas, K., Egan, C. A., and Issa, P. Charbel, “Fundus Autofluorescence Imaging in Macular Telangiectasia Type 2: MacTel Study Report Number 9.”, Am J Ophthalmol, vol. 228, pp. 27-34, 2021.
2020
K. J. Meador, Pennell, P. B., May, R. C., Van Marter, L., McElrath, T. F., Brown, C., Gerard, E., Kalayjian, L., Gedzelman, E., Penovich, P., Cavitt, J., French, J., Hwang, S., Pack, A. M., Sam, M., Birnbaum, A. K., and Finnell, R., “Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy.”, Neurology, vol. 94, no. 14, pp. e1502-e1511, 2020.
F. Hamzabegovic, Goll, J. B., Hooper, W. F., Frey, S., Gelber, C. E., and Abate, G., “Flagellin adjuvanted F1/V subunit plague vaccine induces T cell and functional antibody responses with unique gene signatures.”, NPJ Vaccines, vol. 5, no. 1, p. 6, 2020.
2019
C. J. Paller, Huang, E. P., Luechtefeld, T., Massett, H. A., Williams, C. C., Zhao, J., Gravell, A. E., Tamashiro, T., Reeves, S. A., Rosner, G. L., Carducci, M. A., Rubinstein, L., and S Ivy, P., “Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination Trials.”, Front Med (Lausanne), vol. 6, p. 122, 2019.
J. Pidala, Martens, M., Anasetti, C., Carreras, J., Horowitz, M., Lee, S. J., Antin, J., Cutler, C., and Logan, B., “Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation.”, JAMA Oncol, 2019.
T. Schonfeld, “Finding Common Ground and Advancing Engagement in Citizen Science.”, Narrat Inq Bioeth, vol. 9, no. 1, pp. 41-45, 2019.
S. Morgello, Gensler, G., Sherman, S., Ellis, R. J., Gelman, B. B., Kolson, D. L., Letendre, S. L., Robinson-Papp, J., Rubin, L. H., Singer, E., and Valdes-Sueiras, M., “Frailty in medically complex individuals with chronic HIV.”, AIDS, vol. 33, no. 10, pp. 1603-1611, 2019.
I. Edun, Gay, K., Sheikh, M., Esterlitz, J., Lynch, D., Pandolfo, M., Gubitz, A., Lungu, C., M. Mendoza-Puccini, C., and Groups, N. I. N. D. S. Friedreich, “Friedreich’s ataxia Common Data Element Review: Updates to the National Institute of Neurological Disorders and Stroke Friedreich’s ataxia (FA) Common Data Element Recommendations: 2018 FA Working Group Review”. 2019.
A. A. King, McKinstry, R. C., Wu, J., Eapen, M., Abel, R., Varughese, T., Kamani, N., and Shenoy, S., “Functional and Radiologic Assessment of the Brain after Reduced-Intensity Unrelated Donor Transplantation for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network Study 0601.”, Biol Blood Marrow Transplant, vol. 25, no. 5, pp. e174-e178, 2019.
2017
P. T. Korthuis, Lum, P. J., Vergara-Rodriguez, P., Ahamad, K., Wood, E., Kunkel, L. E., Oden, N. L., Lindblad, R., Sorensen, J. L., Arenas, V., Ha, D., Mandler, R. N., and McCarty, D., “Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.”, Addiction, vol. 112, no. 6, pp. 1036-1044, 2017.
J. Nyombayire, Anzala, O., Gazzard, B., Karita, E., Bergin, P., Hayes, P., Kopycinski, J., Omosa-Manyonyi, G., Jackson, A., Bizimana, J., Farah, B., Sayeed, E., Parks, C. L., Inoue, M., Hironaka, T., Hara, H., Shu, T., Matano, T., Dally, L., Barin, B., Park, H., Gilmour, J., Lombardo, A., Excler, J. - L., Fast, P., Laufer, D. S., and Cox, J. H., “First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.”, J Infect Dis, vol. 215, no. 1, pp. 95-104, 2017.
2015
A. A. Forcehimes, Bogenschutz, M., Sharma, G., Wilson, K., and Moyers, M., “Fidelity Monitoring Model for an MI-Based Brief Intervention”, in 77th Annual Meeting of the College on Problems of Drug Dependence (CPDD), Phoenix, AZ, 2015.
2014
L. R. Baden, ,, Seaman, M. S., Johnson, J. A., Tucker, R. P., Kleinjan, J. A., Gothing, J. A., Engelson, B. A., Carey, B. R., Oza, A., Bajimaya, S., Peter, L., Bleckwehl, C., Abbink, P., Pau, M. G., Weijtens, M., Kunchai, M., Swann, E. M., Wolff, M., Dolin, R., and Barouch, D. H., “First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 Env (IPCAVD 002)”, J Infect Dis, vol. 210, pp. 1052-1061, 2014.
L. R. Baden, Walsh, S. R., Seaman, M. S., Johnson, J. A., Tucker, R. P., Kleinjan, J. A., Gothing, J. A., Engelson, B. A., Carey, B. R., Oza, A., Bajimaya, S., Peter, L., Bleckwehl, C., Abbink, P., Pau, M. G., Weijtens, M., Kunchai, M., Swann, E. M., Wolff, M., Dolin, R., and Barouch, D. H., “First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002).”, J Infect Dis, vol. 210, no. 7, pp. 1052-61, 2014.
2013
J. Haberer, Mugo, P., Kibengo, F., Mutua, G., van der Elst, E., Kamali, A., Sanders, E., Barin, B., Bangsberg, D., and Priddy, F., “Factors Influencing Adherence Behavior for Daily and Intermittent Regimens of Pre-Exposure Prophylaxis (PrEP) Among Men Who Have Sex With Men (MSM) in Kenya”, in Adherence 2013, Miami, FL, 2013.
E. M. Alonso, Martz, K., Wang, D., Yi, M. S., Neighbors, K., Varni, J. W., Bucuvalas, J. C., and FOG), T. Studies of, “Factors Predicting Health Related Quality of Life in Pediatric Liver Transplant Recipients in the Functional Outcomes Group”, Pediatr Transplant, vol. 17, pp. 605-611, 2013.
E. M. Alonso, Martz, K., Wang, D., Yi, M. S., Neighbors, K., Varni, J. W., and Bucuvalas, J. C., “Factors predicting health-related quality of life in pediatric liver transplant recipients in the functional outcomes group.”, Pediatr Transplant, vol. 17, no. 7, pp. 605-11, 2013.
M. J. Cohen, Meador, K. J., Browning, N., May, R., Baker, G. A., Clayton-Smith, J., Kalayjian, L. A., Kanner, A., Liporace, J. D., Pennell, P. B., Privitera, M., Loring, D. W., and Group, T. N. E. A. D. Study, “Fetal Antiepileptic Drug Exposure: Adaptive and Emotional/Behavioral Functioning at Age 6 Years”, Epilepsy Behav, vol. 29, pp. 308-315, 2013.
M. J. Cohen, Meador, K. J., Browning, N., May, R., Baker, G. A., Clayton-Smith, J., Kalayjian, L. A., Kanner, A., Liporace, J. D., Pennell, P. B., Privitera, M., and Loring, D. W., “Fetal antiepileptic drug exposure: Adaptive and emotional/behavioral functioning at age 6years.”, Epilepsy Behav, vol. 29, no. 2, pp. 308-15, 2013.
K. J. Meador, Baker, G. A., Browning, N., Cohen, M. J., Bromley, R. L., Clayton-Smith, J., Kalayjian, L. A., Kanner, A., Liporace, J. D., Pennell, P. B., Privitera, M., and Loring, D. W., “Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study.”, Lancet Neurol, vol. 12, no. 3, pp. 244-52, 2013.
K. J. Meador, Baker, G. A., Browning, N., Cohen, M. J., Bromley, R. L., Clayton-Smith, J., Kalayjian, L. A., Kanner, A., Liporace, J. D., Pennell, P. B., Privitera, M., Loring, D. W., and Group, N. E. A. D. Study, “Fetal Antiepileptic Drug Exposure and Cognitive Outcomes at Age 6 Years (NEAD Study): A Prospective Observational Study”, Lancet Neurol, vol. 12, pp. 244-252, 2013.
R. C. May, “Finding Your First Industry Job”, in International Biometric Society - Eastern North American Region (ENAR), Orlando, FL, 2013.
L. R. Baden, ,, Seaman, M. S., Tucker, R. P., Krause, K. H., Patel, A., Johnson, J. A., Kleinjan, J., Yanosick, K. E., Perry, J., Zablowsky, E., Abbink, P., Peter, L., Iampietro, M. J., Cheung, A., Pau, M. G., Weijtens, M., Goudsmit, J., Swann, E., Wolff, M., Loblein, H., and Dolin, R., “First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)”, J Infect Dis, vol. 207, pp. 240-247, 2013.
L. R. Baden, Walsh, S. R., Seaman, M. S., Tucker, R. P., Krause, K. H., Patel, A., Johnson, J. A., Kleinjan, J., Yanosick, K. E., Perry, J., Zablowsky, E., Abbink, P., Peter, L., M Iampietro, J., Cheung, A., Pau, M. G., Weijtens, M., Goudsmit, J., Swann, E., Wolff, M., Loblein, H., Dolin, R., and Barouch, D. H., “First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).”, J Infect Dis, vol. 207, no. 2, pp. 240-7, 2013.